Immunotherapy is a type of cancer treatment that works by helping the body’s own immune system recognise and attack cancer cells. While traditional treatments like chemotherapy target rapidly dividing cells directly, immunotherapy focuses on boosting the natural defences of the patient to find and destroy tumours more effectively. In the UK, this treatment has become a standard option for many lung cancer patients, particularly those with specific genetic markers or advanced stages of the disease.
What We’ll Discuss in This Article
- The biological mechanism of how immunotherapy identifies cancer cells.
- The specific types of immunotherapy drugs used for lung cancer in the UK.
- How immunotherapy differs from traditional chemotherapy treatments.
- The process of receiving immunotherapy through the NHS.
- Common side effects and how the immune response is monitored.
- Eligibility and the role of PD-L1 testing in treatment planning.
The Mechanism of Immunotherapy in Lung Cancer
Immunotherapy works by blocking the “checkpoints” that cancer cells use to hide from the immune system, allowing white blood cells to attack the tumour. Cancer cells often produce specific proteins that send a “stop” signal to T-cells, which are the immune system’s primary defenders. Immunotherapy drugs, known as checkpoint inhibitors, interfere with these signals so that the T-cells can recognise the cancer as a threat and begin to destroy it.
Immunotherapy is a type of treatment that stimulates the immune system to fight cancer. In the context of lung cancer, these drugs are often used when the cancer is advanced or has spread to other parts of the body. The National Institute for Health and Care Excellence (NICE) recommends several immunotherapy options for non-small cell lung cancer based on the level of specific proteins found in the tumour.
How Immunotherapy Helps Patients
The primary benefit of immunotherapy is its ability to provide long-term control of lung cancer by training the immune system to remember and target cancer cells. Because the immune system is adaptive, it can continue to protect the body even after the initial treatment sessions have concluded. For many patients in the UK, this approach has led to improved outcomes and a better quality of life compared to older systemic treatments.
Unlike chemotherapy, which can damage healthy cells throughout the body, immunotherapy is more targeted toward the interaction between the immune system and the tumour. This often results in a different profile of side effects. While it does not work for every patient, those who do respond often see significant shrinking of tumours and a reduction in respiratory symptoms like breathlessness or persistent coughing.
Comparison Between Immunotherapy and Chemotherapy
It is important for patients to understand how these two common systemic treatments differ in their approach and impact on the body.
| Feature | Immunotherapy | Chemotherapy |
| Primary Target | The body’s immune system. | Rapidly dividing cells (cancer and healthy). |
| Method of Action | Unmasks cancer cells for immune attack. | Directly kills or stops cells from growing. |
| Common Side Effects | Inflammation-related (e.g., skin rash, fatigue). | Nausea, hair loss, and lowered blood counts. |
| Duration of Effect | Can provide long-lasting “immune memory.” | Usually works only while drugs are in the system. |
| Eligibility | Often depends on specific protein markers (PD-L1). | Widely applicable to many cancer types. |
Receiving Treatment and Monitoring Side Effects
Immunotherapy is typically delivered through an intravenous (IV) drip in a hospital or specialist clinic, with sessions usually occurring every two to six weeks. Before starting, patients undergo a PD-L1 test on a sample of their tumour to see how likely the treatment is to be effective. During the sessions, which take about 30 to 90 minutes, patients can usually relax, read, or listen to music.
Because immunotherapy “wakes up” the immune system, side effects are usually related to inflammation in different parts of the body. Common issues include feeling very tired, itchy skin rashes, or joint pain. In some cases, the immune system can attack healthy organs like the lungs or bowels, which requires careful monitoring by the medical team. UK oncologists use regular blood tests and physical assessments to ensure the immune response remains focused on the cancer and does not cause excessive inflammation elsewhere.
Conclusion
Immunotherapy helps lung cancer patients by enabling their immune system to recognise and destroy cancer cells more effectively. It is a precise and evidence-based treatment used in the UK to improve long-term outcomes for those with specific types of the disease. While it can cause side effects related to an overactive immune system, it is a cornerstone of modern cancer care. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Is immunotherapy better than chemotherapy?
It is not necessarily “better” but works differently; for some patients, it is more effective, while for others, chemotherapy remains the primary option.
Will I lose my hair with immunotherapy?
Hair loss is very uncommon with immunotherapy alone, though it can occur if the treatment is combined with chemotherapy.
How do I know if I am eligible for immunotherapy?
Eligibility is determined by doctors using a PD-L1 test on your tumour tissue to see if the cancer is likely to respond to immune-based drugs.
Can immunotherapy cure lung cancer?
While it can significantly shrink tumours and keep the cancer under control for long periods, it is generally used as a management tool for advanced stages.
How long do I need to stay in the hospital for a session?
The infusion itself usually takes less than two hours, and most patients go home on the same day as their treatment.
What is a “checkpoint inhibitor”?
It is a type of drug that blocks proteins that stop the immune system from attacking cancer cells, essentially “releasing the brakes” on the immune response.
Are the side effects of immunotherapy immediate?
Some side effects can appear quickly, but others may not develop until several weeks or even months into the treatment course.
Authority Snapshot (E-E-A-T Block)
This guide provides factual, evidence-based information on immunotherapy for lung cancer, strictly aligned with NHS and NICE clinical guidelines. The content is reviewed by Dr. Stefan Petrov, a UK-trained physician with extensive experience in general medicine, surgery, and emergency care. Our commitment to UK medical standards ensures this information is safe and accurate for patient education.
